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Abstract
Few travel health measures are as controversial as the use of coca leaves at high altitude; yet, there appears
widespread ignorance among health professionals and the general public about coca, its origins as well as its
interesting and often flamboyant history. Equally, the cultural and traditional significance to Andean people is not
recognised. The coca leaves contain many alkaloids, one of which, cocaine, has gained notoriety as a narcotic,
leading to the mistaken idea that coca equals cocaine. This article contrasts coca with cocaine in an attempt to
explain the differences but also the reasons for this widespread misconception. By its very nature, there may never
be scientific ‘proof’ that coca leaves do or do not work for travellers at altitude, but at least a solid knowledge of
coca, and how it differs from cocaine, provides a platform for informed opinions and appropriate critical views on
the current confusing and contradictory legal situation.
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The use of the coca plant not only preserves the health
of all who use it, but prolongs life to a very great old
age and enables the coca eaters to perform prodigies of
mental and physical labor.
(John Pemberton, Atlanta Constitution, 1885)
Introduction
Few travel health measures are as controversial as the
use of coca leaves at high altitude. An informal brain-
storming exercise among health professionals and mem-
bers of the public yielded a number of reasons: cultural
superiority, fear, unease, self-righteousness, but above all
ignorance, confusion with cocoa, and the mistaken idea
that coca equals cocaine. This paper aims to de-mystify
the topic by informing about the leaf, its historical and
cultural background, its physiological properties includ-
ing its use at high altitude – where it crosses paths with
travel medicine – as well as its progression to the
enthusiastic welcome in the industrial world of the nine-
teenth century. By necessity, this article includes a sum-
marised coverage of key aspects of cocaine to allow an
objective assessment and the distinction between natural
leaf and isolated alkaloid (and illegal drug) cocaine
hydrochloride.
Altitude tourism
The increasing popularity of adventure and sports tourism
as well as better access to more remote areas see more
travellers at ‘high altitude’ (commonly > 2500m.a.s.l.).
Peaks in the Himalayas (Pakistan, India, Nepal, China) rise
to above 8000m, in the Andes to above 6000m, and over
500 peaks in the European Alps are higher than 3000m.
The North American Rocky Mountains are as popular as
Mt Kenya (5199m) or Mt Kilimanjaro (5895m) in Africa
or Aoraki/Mt Cook (3724 m) in New Zealand. With the
melting of last remnants of snow at the previous ski
resorts of Chacaltaya/Bolivia (5421 m) and Mérida/
Venezuela (4767 m), the currently highest ski fields are
in Breckenridge/Colorado (3914 m) and the Kleines
Matterhorn in Zermatt/Switzerland (3883 m). Train
lovers can ride the Qinghai-Tibet Railway (5072 m), the
Ferrocarril Central Andino (4782 m) or the Argentinian
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Train to the Clouds (4220 m). Cities such as Lhasa
(3650 m) or La Paz (3640 m/Airport El Alto 4061 m)
add to the multiple opportunities of exposure to high
altitude. Still missing from travel medicine discussions
are skydivers who typically fly within minutes to jump-
ing heights of around 4000 m and above. Anecdotal
evidence suggests altitude symptoms that are separate
from fear, panic or exhilaration.
Altitude medicine
The first known mention of an altitude-related influence
on humans and animals originates in the third decade
BC in China [1]. In 1590, Jesuit José Acosta was the first
to document graphically the symptoms of altitude sick-
ness he suffered while crossing the Andes [2]. Potential
positive effects of altitude on the human body have been
explored, for example, in sports training camps [3].
However, the literature generally focuses on acute alti-
tude mountain sickness (AMS), high altitude pulmonary
oedema (HAPE) and high altitude cerebral oedema
(HACE). Discussion on epidemiology, clinical presenta-
tion and pathophysiology is ubiquitous and can be
obtained elsewhere. Important for this paper is the
current knowledge base on prevention and treatment
apart from general gradual ascent or rapid descent. The
current gold standard is the use of acetazolamide even
though its efficacy in preventing AMS incidents has been
questioned [4, 5]. Elsewhere, it has been identified as
carrying a higher risk for AMS [6]. Other substances are
dexamethasone, ibuprofen, previously ridiculed Gingko
biloba, caffeine [7] and many others. While pre-
treatment with Gingko biloba (EGb761) prevented AMS
[8] or reduced its severity [9], other results were indiffer-
ent [10, 11], with Gertsch [12] starting the experiment at
a baseline at 4000m which appears far too late in the as-
cent to draw meaningful conclusions. Too few studies
employing different protocols, and different sources of
preparation of this and other substances, point to the
need for more rigorous investigations, yet, the methodo-
logical difficulties are formidable.
Coca leaves and the Andean traveller
Virtually all travellers to the Andes will come across
coca leaves and coca tea. The tea is served in eateries,
trains and accommodations from the very basic to the
most luxurious. People picking up arrivals at high alti-
tude airports typically come armed with a hot thermos
of coca tea to prevent soroche (AMS). Coca tea may
come as a few hard, dry leaves in hot water looking
pretty but doing little, or as commercially available tea-
bags which, the leaves being chopped up, colour the hot
water quickly; the slightly bitter taste is apparent, and an
effect noticeable. Even better would be the chewing of
the leaves though this is less popular with travellers.
Some fanciful application in biscuits, ice cream or lollies
have no effect. For many travellers, drinking coca tea is
normal, others, due to ignorance, may feel like criminals
[13]. For some it may be an exciting challenge [14],
others understand coca as part of a cultural discourse
with the local people [15]. Tourists visiting mines in
Bolivia typically purchase coca with dynamite, fuses, al-
cohol and cigarettes as gifts for the miners to use and to
offer to El Tío (the devil) for protection [16].
Travel medicine research and coca
A number of reviews and guidelines provide recommen-
dations for the prevention and treatment of AMS; some
omit coca [17, 18], others point out that there are no ef-
ficacy studies of coca and coca products [19, 20], though
calling coca ‘a weak cocaine’ [20] misses the mark.
A few descriptive studies include coca in their re-
ports. A study of trekkers’ and guides’ knowledge of
AMS prophylaxis in Nepal’s Everest region showed
poor understanding of acetazolamide use [21], a finding
also described elsewhere [22]. Trekkers also carried
coca, among other preparations, but no further infor-
mation is given. Post-trip questionnaires of 162 adults
to Peru/Bolivia and Kenya/Tanzania regarding preva-
lence of and risk factors for AMS included a question
on coca leaves in the South American group where al-
most 50% of all travellers used ‘coca leaves’, presumably
because predominantly non-medical sources were con-
sulted [6]. However, important information about the
definition of ‘coca leaves’ is missing, e.g. chewing of dry
leaves, dry leaves in hot infusions, infusions with tea-
bags, as well as a plethora of factors that would make a
link to AMS prevalence meaningful. Another attempt
to gauge 100 travellers’ knowledge of AMS and its
source was made in Cusco/Peru [23]. The questionnaire
appears underdeveloped and poorly edited; the paper
only describes that only 9% of respondents knew of ac-
etazolamide’s preventative properties. As questions to
prophylactic measures were open-ended, it is highly
likely that many travellers will have mentioned coca.
Not discussing the entire range of travellers’ chosen
measures clearly is a missed opportunity for a balanced
report. Another missed opportunity to gauge travellers’
coca use arises from a large (n = 5988) study on self-
reported health problems among visitors to Cusco [24].
Altitude sickness prophylaxis had been prescribed pre-
travel to 16% of travellers, one must assume acetazol-
amide. Altitude sickness was reported by 43% of travel-
lers; 75% applied self-treatment (for all illnesses). Since
that many treated themselves, it is highly likely that
coca featured prominently. Detailed questions of type
of preparation and use, in such a large sample, would
have delivered helpful insight.
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Another study in Cusco examined AMS impact on
991 travellers [25]. The use of coca products in pre-
travel advice was recalled by over 5%; to prevent AMS,
almost 63% used coca products, though different types
of products with different efficacy, e.g. virtually none in
lollies, were bundled together. The conclusion that the
use of coca leaf product was associated with increased
AMS frequency is not supported by the study design. It
does not capture when and how coca was used, e.g. was
it used before even the slighted symptoms appeared
(such as on arrival), or was it used (long) after the onset
of symptoms, when it cannot be called prevention any-
more? How can one be certain what subjects meant in a
questionnaire? Of course, people remember coca once
they have symptoms; this is not prevention and leads to
questionable conclusions.
One study attempted to describe 136 travellers’ use of
coca in Peru and Bolivia with 15 closed questions [26].
Almost 90% took coca; of those, 55% drank coca tea,
22% chewed the leaves, and 23% did both. Forty-two
percent wished to prevent AMS, 22% treated AMS, 36%
cited other reasons. The reported effect is described but
lacks meaning. Fifty-one percent reported no noticeable
effect. Since there is no standardised dose, it is unclear
how much was ingested. Apart from that, if taken for
prevention and it worked – how would anyone know if
it had or had not an effect – or if the individual simply
had no symptoms? Thirty-one percent felt a desirable
effect – again, how did they know that this was due to
coca and not the excitement of the trip? Undesirable ef-
fects were reported by 19%, such as nausea and abdom-
inal pain. There is no way travellers would have been
able to specify that this was due to coca and not altitude,
jetlag, food etc. The study listed a number of limitations
correctly but was not able to add to the current limited
knowledge. Finally, a ‘placebo-controlled, single-blinded,
non-randomized’ study of homoeopathic coca use at
Everest Base Camp described a significant reduction of
the effects of altitude on a small sample of trekkers [27].
The study’s weak methodology is acknowledged but the
paper omits one crucial part completely, the used hom-
oeopathic preparation. On request, any disclosure of the
nature of the compound or analysis was declined. For
this reason, this paper should be excluded from any fur-
ther discussions on the efficacy of coca.
What is coca?
The coca shrub was named Erythroxylum by Browne in
1756 (Erythroxylon by Linneus in 1759) [28]. Over 200
different species of the bush can be found throughout
South America, the Caribbean, Africa, India, tropical
Asia and Oceania [29], not all containing alkaloids. The
two species cultivated in South America are E. coca and
E. novogratense, each with two variations adapted to
different topography, soil conditions and climate. The
best conditions are found in the subtropical valleys on
the Andean Amazon slopes [30]. Apart from fibres, es-
sential oils (flavour/aroma), minerals and vitamins, coca
leaves contain generally a number (up to 15) of alkaloids
in varying amounts, such as hygrine, cuscohygrine, cis-
and trans-cinnamoylocaine, nicotine, methylecgomine,
tropococaine, tropinone, benzoylecgonine, and cocaine
[e.g. 31–34]. Because of the focus on cocaine, there has
been little research into the properties of the leaf’s
other alkaloids. This is disappointing as it is highly
likely that the substances act synergistically to pro-
duce the effect of coca [35], and more research on
the entire leaf is needed [36].
Whereas the individual alkaloids may be of interest to
some only, the nutritional value of coca leaves with its
relatively high levels of certain minerals and vitamins
has been celebrated for decades after the famous ‘Har-
vard-Study’ [34]. Based on this analysis, the use of coca
in food, particularly as coca flour, was promoted as a
cheap local substance to improve the nutrition, espe-
cially of the poor. The study only advised caution re-
garding the alkaloids and possible insecticide residue.
Later findings that coca had no nutritional benefits or
even adverse effects were disappointing though the study
acknowledged that there might be other factors affecting
the bioavailability of nutrients [33]. One must be careful
assigning coca as the cause of malnutrition when sup-
pression of hunger is typically based on lack of sufficient
food in the first place. Feeding people properly de-
creased chewing in an earlier experiment [37] but more
work needs to be done to avoid pro-and anti-coca re-
search bias.
Apart from the traditional topical application as pow-
der or poultice, the hard sun-dried leaves are usually
consumed as tea or by ‘chewing’. Chewing is not the
right word as travelling novice chewers quickly find out.
Chewing the leaves produces a non-enjoyable accumula-
tion of stubborn small hard bits in one’s mouth. Rather,
as Unanue [38] described, it is more of a ‘sucking’
(today, one is invited by locals to suck (chupar) coca).
The leaves are placed one by one in the mouth, briefly
broken up, and moved around with the tongue to form a
quid that is then moved to the buccal cavity where it is
gradually moistened by saliva. With a saliva-moistened
stick, a little lime (llipta), e.g. ashes of burnt seashells,
limestone, or plants but also soda bicarbonate, is added
to enhance the effect though it is still unclear if this im-
proves the flavour, promotes salivation, or releases alka-
loids [39]. The ‘chewing’ then consists of sucking the
copious saliva until the quid is spent. Travellers gener-
ally forgo the adjuvant. A chewer is recognised by the
bulge on one side of the face rather like a qat chewer’s
in Southern Arabia but that plant is entirely different
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(Catha edulis), and only fresh new growth is used. How-
ever, travellers to both locations will note a similar
effect.
Cultural significance, traditional use and a ‘sprinkling’ of
research
Coca has always played an important role in Andean life
[40] on two levels. First, coca is a strong marker of cul-
tural identity for many Andean communities [41, 42]. It
is crucial in acknowledging and maintaining social bonds
[29]. Friendship and affection are demonstrated by
chewing together; refusal is perceived antisocial [42]. Re-
ligious aspects of coca are evident through shamans’ div-
inations, at animal sacrifices and burials, but also in
everyday life such as a gift to a potential bride’s father,
during carnivals and celebrations, even as inspiration for
weavers [42]. The chewing of a cocada is a measure of
time indicating 45min of walking comfortably for 2 km
of steep terrain or 3 km of level grounds [42]. Strict eti-
quette rules the highly ceremonialised handling, sharing
and use of the leaves [41]. Coca is part of important eco-
nomic activities on a local level, e.g. rural women trading
in traditional medicines [43], and nationwide [44].
Second, historically and today, coca is used for medi-
cinal purposes. It works as a local anaesthetic in local
applications (powder/poultice), by chewing against tooth-
ache or pain in mouth and throat, or as a tea for gastro-
intestinal complaints [30]; it eases the pain of childbirth
and hastens labour [42]. Even today, Andean immigrants
to the UK use coca, a cultural keystone species, in legal
products, such as teabags, sweets and flour [45]. Historic-
ally, to facilitate work, coca was chewed three times per
day, before starting, halfway through the day, and shortly
before finishing [38]. Then and today, coca works as a
stimulant, suppresses appetite and fatigue, and alleviates
the effect of altitude [29]. These latter qualities created the
enigma of coca and intermittent flurries of research, gen-
erally on high altitude residents, not new arrivals [46].
In the late 1940s and early ‘50s, research (using Western
tests) linked coca chewing to mental deficiencies, low
intelligence and unfavourable personality traits in indigen-
ous people [37, 47]. Studies on coca appear to arrive in
bursts, depending on prevailing worldviews. Renewed
interest in the 1960s and ‘70s resulted in a number of hap-
hazard studies on Andean residents to pinpoint, in typical
reductionist fashion, what exactly caused the alleged abil-
ity to withstand cold, hunger and fatigue. A puzzling study
on six coca chewing Machiguenga residents of the cloud
forests (2300m) led nowhere [48]. Coca chewing in the
Peruvian village of Cachicoto (2400m) was associated
with inferior nutritional status, inferior personal hygiene,
and increased hookworm anaemia, concluding that
cocaine kept villagers in a permanent state of malnutrition
[49]. At least, the researchers acknowledged the
complexity and interaction of environmental and host
factors. Residents of the Peruvian village Nuñoa (4000m)
assisted with the next three studies. One reported that
coca (in contrast to imbibing alcohol) had no effect when
exposing one foot to 0 °C for 1 hr (n = 29) [50]. No par-
ticular result was obtained from having six chewers and
six non-chewers step on a box repeatedly for 10min at
different rates and box heights [51]. When 14 male vil-
lagers were exposed to 15.5 °C for 2 h wearing shorts and
reclining on metal cots with a blanket, it was concluded
that coca might conserve body heat [52]. The possible ef-
fects of coca chewing on erythropoiesis have been sug-
gested [53]. An Amazon expedition in 1977 was the
setting for the determination of the amount of cocaine in
the blood of three Eurasians and one local [54].
Twenty years later, experimental evidence of 22 men
from the Bolivian Altiplano (3800 m) suggested a physio-
logical effect of coca chewing on their better ability to
sustain strenuous work for 60 min [55] but not improved
maximal exercise capacity or increased work efficiency
[56]. Interestingly, results of a glucose tolerance experi-
ment suggest that habitual coca chewers, due to an an-
tagonistic action of coca metabolites on insulin, do not
present hypoglycaemia caused by hypobaric hypoxia
[57], a fact assumed 20 years earlier [58]. More recent
work found no difference in aerobic capacity between
chewers and non-chewers [59] but biochemical changes
enhanced physiological performance at high altitude
[60]. These authors point to the important distinction
that this effect could be due to flavonoids in the leaf, not
the extremely small amount of cocaine (chewing of 30 g
of leaves resulted in 98 ng [= 0.000000098 g]) of cocaine
[60]. That other alkaloids in the leaf are biologically ac-
tive, e.g. reduce food consumption, has been demon-
strated before [61]. None of those studies, of course, has
considered possible hereditary factors that contribute to
altitude adaptation in Andean residents [62], and how
this influences any comparison with the effect of coca
on travellers not benefitting from genetic variations
through many generations raised at altitude. Finally,
chewing did not induce genetic instability in cells on the
oral cavity, and no adverse health effects in chewers
were associated with DNA damage at moderate con-
sumption [63].
The history of coca
The history of the coca leaf is fascinating. For an ex-
quisite and extraordinarily comprehensive discussion,
the History of Coca by Mortimer MD [64], or its shorter
version [65] is highly recommended. While his work
ends with the beginning of the twentieth century, many
sources mentioned below cover the remaining time
very well.
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From prehistory to the Spanish conquest
Historic summaries usually start with the first Spanish
accounts of coca after the sixteenth century conquest.
However, signs of coca cultivation date back to thou-
sands of years, from Nicaragua to Chile [66]. Lime con-
tainers have been found from as early as 8000 BC [42].
Dental evidence and hair samples, together with mum-
mies, ‘coquero’ ceramics, burial offerings and signs of
prehistoric lime production suggest that coca leaf chew-
ing was relatively common from 2500 BC in Peru [67]
and 1000 BC in Chile [29]. In some regions, a magical
function of coca may have restricted its use to important
persons in a social group [30]. Coca was used in high-
lands and lowlands alike [66].
The use of coca was long established when in the elev-
enth century the first Inca Manco Capac arrived to start a
formidable empire. Several romantic myths tell of the sa-
cred origin of the plant (mama coca) whose divine powers
restricted its use to the royal élite (the descendants of the
Sun god Inti) for religious, social and political purposes,
though permission could be given to others as a special
favour. Coca chewing by commoners could be punished
severely but the use of leaves for offerings was permitted
[30, 39]. Coca may have been used for medicinal purposes,
such as for trepanations [39]. A Fray Tomás Ortíz is said
to have mentioned coca first when travelling in Venezuela
but Amerigo Vespucci’s letter of 1504 provides the pos-
sibly first description of the coca chewing technique and
its effect against thirst [30].
A weakening Inca empire saw relaxed rules around the
use of coca by the general public; with the conquest
changing the entire political, social, cultural, religious
and economic landscape after 1532, coca was chewed by
all [30, 39]. Pizarro’s men mentioned coca and its special
stores [68] but de la Vega [69], and later Unanue [38],
reported the Spaniards’ prejudice and ignorance. The
Spanish were in two minds about coca. The clergy and
some conquistadors saw the ‘devil’s leaf’ [42] as a barrier
to conversion and a symbol of persistent idolatry [37,
39], whereas the owners of mines and plantations gave
coca to the miners, workers, runners, and porters to get
maximum work output at minimum expense [30]. Du-
plicitous Philip II supported the supply of coca to
workers but, at the same time, instructed missionaries to
oppress its use [39]. Large coca production and trade
began; many in Spain got very rich [30, 42]. The bishop
of Cusco was a major coca dealer himself [46]. Indians
from the highlands died not only from the well-known
adverse effects of conquest and forced labour but, sent
to work in plantations, succumbed to humid heat and
tropical diseases [30, 70]. Few Spaniards chewed, some
using sugar instead of llipta [38].
In 1653, Jesuit Bernabé Cobo was the first to mention
the anaesthetic effect of coca against toothache following
local advice not to pull his healthy tooth but chew coca
instead [30]. In the eighteenth century, Antonio Julian
suggested coca for the working classes in Spain to im-
prove health and productivity, and as a cheap substitute
for coffee and tea. Consequently, Spain could have a
supply monopoly in Europe [39]. In his 1794 disserta-
tion, Unanue cites a Doctor Don Pedro predicting times
when there would be abundant trade in coca with the
rest of the world [38]. He was right.
Coca in the industrial world
Having observed coca-chewers in South America, Italian
neurologist Paolo Mantegazza returned to Italy in 1858
to recommend coca highly as an internal medicine based
on his self-experiments. Coca was received enthusiastic-
ally and, by the end of the nineteenth century, many
physicians prescribed the chewing of leaves as conducive
to good health. By 1855, German chemist Friedrich
Gaedcke had separated erythoxylin (=cocaine) from the
leaf and in 1859, Albert Niemann isolated purified co-
caine [42]. His student Wilhelm Lossen determined the
molecular formula C17H21NO4 in 1865 [68]. From here
on, the thousands of years old history of coca continues,
and the now over 150-year-old history of cocaine begins,
first as a natural component of the leaf, later as the
isolated alkaloid. The excitement of the miraculous sub-
stance led to several simultaneous developments. No
summary could do the enthusiastic descriptions of appli-
cations, (self-)observations and success stories by a
multitude of medical doctors, scientists, and quacks just-
ice, and the perusal of either originals or fascinating
comprehensive historical reviews [eg. 39, 64, 65, 71–73]
is highly recommended. In order to describe and explain
coca, it is imperative to highlight the difference to
cocaine. The literature on the following sub-sections’
themes is vast, educative and interesting. Space con-
straints only allow a severely summarised representation
of key aspects.
The invigorating tonic
In 1863, the Corsican chemist Angelo Mariani produced
the first stable preparation of coca by adding the extract
to Bordeaux wine which not only made him fabulously
wealthy but his many customers very happy. His ‘Vin
Mariani’ sold all over the world as a ‘most efficacious
tonic’. He also produced an elixir, pâte (Lozenges), pas-
tilles and tea [74]. The wine received thousands (13
volumes in the British Library) of recommendations and
endorsements, including from Popes Leo XIII, who
drank copious amounts and awarded Mariani a Vatican
medal, and Pius X, monarchs (Queen Victoria, Kings
George I of Greece and Oscar II of Sweden/Norway),
but also celebrities such as Thomas Alva Edison, Jules
Verne, Eleonora Duse or Auguste Rodin [75]. It made
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people feel good, probably because Vin Mariani con-
tained 0.12 grain cocaine per fluid ounce. One recom-
mended glass of wine (1/2 glass for children) contained
6 fluid ounces [76] for a total ‘dose’ of 0.72 grain or
46.65 mg cocaine.
Mariani’s reputation was marred by inferior imitators,
one of them a John Pemberton of Atlanta. Pemberton,
who possibly hoped to break his morphine habit with
coca, produced ‘French Wine Coca’, adding caffeine from
the West African kola nut. He announced endorsements
‘by over 20,000 of the most learned and scientific medical
men in the world’ [76, p.23]. Prohibition hampered his
success, and the alcohol had to be removed from the bev-
erage. Substitution with water was unsatisfactory but
when mixed with soda water by lucky mistake, a drink
was created that would conquer the world: Coca-Cola. Al-
leged crimes by black men against white women focused
the investigation on the cocaine content of the drink
which, reportedly, had been removed by 1903, an action
that haunts the company to this day, stubbornly sticking
to strategic untruths. Perused by business students around
the world, the history of the beverage and of the com-
pany’s aggressive business practices, including child labour
and rampant racism, make for riveting reading [76, 77],
especially for health professionals. Remarkable is that, to
this day, the presence of cocaine in Coca-Cola ever is be-
ing denied, and much is spent on ‘myth busting’ advertise-
ments. In 2009, Coca-Cola was forced to issue corrective
advertisements in Australian newspapers. The rectification
of the denial of the historic cocaine content was conveni-
ently ‘forgotten’ [78]. The company has been on the brink
of disaster many times afterwards. Starting off as a refresh-
ing ‘pick-me-up’, the beverage’s ingredients kept infuriat-
ing, from alcohol and cocaine to ‘teeth-rotting acid’ and
obesity-inducing sugar. It is equally remarkable that there
seem few independent publications on the company or
transparency on the Stepan-Company which is said to im-
port, with special permission, coca leaves and decocainise
them for Coca-Cola. A statement that Coca-Cola ceased
using coca for flavouring in 2000 [79] could not be
verified.
Coca and the scientific community
Ubiquitous publications in the 1800s by medical doctors
and others praised the use of coca (and its cocaine) for
its most marvellous ability to alleviate or cure all
manners of afflictions. Among those were asthma, colds,
eczema, hysteria, melancholy, exhaustion, overwork, ‘af-
fliction of timidity in society’, weak nervous systems,
depression, digestive disorders, opium habit and alcohol-
ism. On the plus side, coca increased and strengthened
pulse, respiration, and urinary excretion, supported sex-
ual activity, provided rosy cheeks and a deeply joyful
sensation of feeling intensively alive, not to mention a
stimulating effect on doctor and patient. The following,
published in the Lancet and the BMJ, rely on self-
experimentation, popular at the time, and minute re-
cording of details. Bennett [80] was disappointed to
notice no particular effect of coca on himself and rather
proceeded to investigate cocaine, theine, caffeine, guar-
anine and theobromine in ‘lower animals’. Historical de-
scriptions from the conquest to nineteenth century
explorers’ dismissive accounts, such as by Poeppig and
von Tschudi (whose attacks on coca Freud called slan-
derous), piqued the interest of two other scientists,
though one [81, 82] could not get the desired result.
Seventy-eight year old Sir Christinson, on the other
hand, extending his experiments to his students and his
own sons, could not praise the benefits of coca enough
[83]. He tested the alleged fatigue and hunger alleviating
properties elaborately and extensively. Chewing specific
amounts of leaves, he felt nothing until he left the house
and started walking 16 miles. He ‘at once … was sur-
prised to find that all sense of weariness had entirely fled
and that [he] could proceed not only with ease but with
elasticity’ (p.530). He had abstained from food and drink
for 9 hrs, felt neither hunger nor thirst on arrival at
home but ‘on dinner appearing in half an hour, ample
justice was done to it’ (p.530). He concluded that chew-
ing coca removed extreme fatigue and prevented it, hun-
ger and thirst are suspended but appetite and digestion
remain unaffected. He suggested a more palatable prep-
aration such as a liqueur that pharmaceutical chemists
could work out ‘it may be hoped, without looking for a
patent’ (p.531). Coca’s wonderful properties also led to
recommendations for tiresome travels [84] and, more re-
cently, naturally occurring cocaine in the leaf has been
found to possess insecticidal properties [85].
Cocaine as medicine
The application of patent medicines and tonics directed
much work on the isolated alkaloid though still often
called ‘coca’, a confusing mistake that persists even
today. Sigmund Freud’s 1884 paper ‘Über Coca’ [86]
praised the impressive qualities of cocaine. He pre-
scribed it liberally to patients and to himself (to over-
come his morphine addiction) and studied therapeutic
outcomes including aphrodisiac effects, frightening his
fiancée with the warning to expect ‘a big wild man with
cocaine in his blood’. Accused of having added cocaine
to morphine and alcohol as the third scourge of human-
ity, he stopped publishing on cocaine in 1887 [87].
At precisely the same time as Freud became famous,
Alfredo Bignon, a French pharmacist in Lima, conducted
numerous experiments on coca and cocaine but is today
entirely ignored and forgotten. His contribution to the
field is remarkable including his experiments with
kerosene-precipitation to produce cocaine from coca,
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‘the Bignon-Process’, a procedure that will surface again
later in this paper. His method started the legal cocaine
boom in Peru. He moved the production to the idyllic
Tyrolian village of Pozuzo in the Amazon region and
sent non-perishable cocaine sulphides to Germany, pre-
dominantly Merck, instead of bulky volumes of perish-
able leaves. This convenience resulted in the German
dominance in science and global marketing of cocaine
for decades [73].
Also in 1884, Freud’s friend, the ophthalmologist Karl
Koller, experimented with cocaine as a local anaesthetic;
its success extended later to dentistry, urology, laryngol-
ogy and other fields, while William Halsted, also in
1884, developed a successful nerve blocking technique
[68]. Like many other physicians who prescribed cocaine
enthusiastically to their patients, families, friends and
themselves, Freud and Halsted joined those who suc-
cumbed to the addictive effects of cocaine. The growing
fear of cocaine, unfortunately, also changed the attitude
towards coca [72]. A revival of the medical use of coca
has been suggested in the 1970s as the abuse potential
in coca leaves is low compared to the isolated alkaloid
[88]. The clinical effects of coca and cocaine must be
kept distinct, e.g. a cocaine user would consume 60%
pure alkaloid nasally or intravenously immediately vs a
coca chewer obtaining 0.5% cocaine in gradual release
over 1 h [35]. More recently, coca chewing as a therapy
for cocaine maintenance has been discussed [89].
Cocaine, the illegal drug
‘Cocaine is a tropane alkaloid that biologically acts as a
serotonin-norepinephrine-dopamine reuptake inhibitor’
[36, p.568]. When the potential for addiction was under-
stood, cocaine became illegal in the US in 1914 and its
use declined. In the 1960s, cocaine use by the rich and
famous encouraged millions to try this expensive and
presumed ‘safer’ drug. The intense enjoyment of cocaine
euphoria leads eventually to a loss of control over ‘intake
and destructive behaviour of procurement … risking
death, medical complications, incarceration, job loss, fi-
nancial ruin and family turmoil’ [90, p.112]. Denial of
this loss of control prevents addicts from seeking treat-
ment. Cocaine dependence involves the brain’s regions
involving reward and motivation, hence perpetuating the
addiction [90].
Cocaine production Today’s cocaine production is
based on Bignon’s process mentioned earlier and starts in
clandestine ‘laboratories’ with rudimentary equipment,
such as gasoline drums and plastic lined maceration pits.
Regardless of the method, the elaborate process involves
the use of, among others, kerosene/gasoline/diesel,
sulphuric acid, lime or caustic soda and much filtering,
heating, neutralizing, and stomping, exposing farmers to
great physical harm. At the end of the process, about 200-
800 kg of leaves turn into 1 kg pasta básica [46, 91] which
is then sent away for further chemical processes to be-
come cocaine hydrochloride powder, ready for use. Ac-
cording to the Global Drug Survey 2018 [92], cocaine
prices in New Zealand and Australian are the highest in
the world at over A$ 300/g, compared to €60–80/g in
Europe and less in South America. Thirteen percent of
Australians surveyed could procure the drug within 30
min. Of great concern is the availability of ‘crack’, a cheap,
highly addictive free-base form of cocaine, making the
drug available to a much larger clientele. Cocaine produc-
tion requires a vast amount of leaves and a solid know-
ledge of chemistry regardless of available YouTube
instructions. Appreciating this process makes the often-
mentioned rationale for banning the import of coca leaf
teabags quite absurd. To make one’s own 1 kg of pasta
básica, upwards of 800,000 teabags would be required. It
is much easier to buy the product.
The legal situation After cocaine was declared illegal in
the US in 1914, a string of International Conventions on
Narcotic Drugs followed in 1925 banning import/export
and in 1931 limiting manufacturing and distributing
narcotic drugs. In 1935, the US Narcotics Bureau ruled il-
legal the export of “Merchandise No. 5” (= coca and kola
extract) which, with monetary persuasion, Coca-Cola
managed to reverse in 1937 [76]. On instigation from
Peru, after a brief fieldwork in Bolivia and Peru in 1949,
the UN Economic and Social Council (ECOSOC) pub-
lished a report on the ‘coca-leaf problem’ [93]. This report
has since been heavily criticised for a number of serious
flaws including prejudiced methodology and racist over-
tones. The fieldwork consisted mainly of ‘conferences’
with a range of people to elicit a wide spectrum of per-
sonal opinions with anti-coca opinions recorded in extra-
ordinary statements on the degenerated lazy Indian race.
Coca was said to affect intelligence and personality leading
to moral decay; people being dirty, smelly, and negligent
underlined their social inferiority. To the Commission’s
credit, the report offered some moderating comments on
some extreme views. Yet, in the end, its recommendations
sided with the available anti-coca leaf chewing literature
and opinions, and advised to limit legal crops for medicine
and science only, and destroy the rest. Complete suppres-
sion of chewing should be achieved in 15 years or fewer
(p.96). Perplexingly, today’s international bans are still
based on this report.
The 1961 Single Convention on Narcotic Drugs (UN)
[94] (amended 1972, 1990, 1999) is still the current legal
document. Article 26 prescribes the uprooting of all wild
coca bushes as well as the destruction of illegally (= not
for medicine/science) cultivated bushes. Article 27 permits
the use of leaves as a flavouring agent (for Coca-Cola).
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Article 49 (e): coca leaf chewing must be abolished within
25 yrs. Coca leaf was (and still is) listed as ‘Drug included
in Schedule I’ [94, 95].
The 1988 UN Convention against Illicit Traffic in
Narcotic Drugs and Psychotropic Substances [96] made
possession, purchase and cultivation of coca leaves a
criminal offence (turning millions of traditional coca
users into criminals). The famous WHO/UNICRI 1995
‘Global study on cocaine use’ concluded that the ‘use of
coca leaf did not lead to noticeable damage to mental
and physical health, that the positive health effects of
coca leaf chewing might be transferable from traditional
settings to other countries and cultures, and that coca
production provided financial benefits to peasants’ [97,
p.223]. The publication of the study was blocked by the
US in the Committee B: 6th meeting under the threat of
withdrawing funds. The WHO in 2006 acknowledged
traditional use for health benefits but added ‘however,
there may be insufficient research data to prove that
using coca leaf brings only health benefits and no nega-
tive health consequence …’ [98]. Clearly, nobody wants
to put a foot wrong. Since 2000, Peru is the only country
exporting coca leaf to the world market (133 tons annu-
ally), the US the only importing country for flavouring
agents and manufacture of cocaine [99].
The legal situation around the coca leaf use is confus-
ing and the conventions contradicting, especially in light
of the 2007 UN Declaration on the Rights of Indigenous
Peoples. In 2013, Bolivia won the case to recognise trad-
itional coca use and registered reservations to exclude
coca leaf from Schedule I despite the objections of the
US and 14 other nations. The complete removal of the
coca leaf from Schedule I has been advocated for, and
options and solutions offered, for decades to no avail
[79, 100–102]. In a legal case in 2017, a Colombian na-
tional in Spain (possibly a victim of profiling) won the
right to import coca leaf powder [103]. Travellers need
to decide for themselves since no guidance is available.
The ‘War on Drugs’ Confusing legislation and a grow-
ing cocaine problem in the US led the Bush administra-
tion to the ideology-driven ‘War on Drugs’. The aim was
to eradicate supply so that demand would cease. At great
cost and with military assistance, coca bushes were to be
uprooted manually in Peru and Bolivia – which forbids
explicitly the use of herbicide for that purpose – and by
glyphosate (trade name Roundup) aerial spraying in
Colombia [104]. Not only did this ‘war’ fail for various
reasons [105–110], the chemical eradication in Colombia
caused serious health and environmental problems even
across the border to Ecuador [108, 111–114]. Glyphosate
also destroyed legal food crops and forests, made the soil
useless for proposed ‘alternative crops’ and poisoned wa-
terways [108, 111, 114]. Despite overwhelming evidence,
the US State Department denied any health impacts and
blamed farmers for the spray damage [111, 114]. A US
official advised the NY Times in 2000 that glyphosate is
‘less toxic than table salt or aspirin’ and the victim’s ac-
counts were ‘scientifically impossible’ [114]. A report
prepared for the Inter-America Drug Abuse Control
Commission in 2005 [115] confirmed that glyphosate‘s
potential risks on human health are ‘essentially negli-
gible’. Today’s evidence is different.
Coca eradication without replacement for local income
is futile. Alternative crops or other means of economic
development can be successful with the right approach
and community involvement [116, 117]. Unfortunately,
as part of the ‘war’, ‘alternative development’ [110] was
designed in boardrooms, heavy-handedly executed and,
most importantly, excluded local community leaders –
and failed [117]. The European Union, for example in
Bolivia, worked with local government and the coca-
growers’ union resulting in sustainable development and
a reduction of drug-related production [117]. Alternative
development is a promising approach with does not
need to exclude the coca leaf. Apart from the traditional
use, more research should explore its use in a variety of
products [118], possibly an insecticide [85] or potential
novel food products as has been suggested for agrofor-
estry trees [119]. The legal situation around the coca leaf
is outdated and unsatisfactory; drug policy reform is ur-
gently needed. It is small wonder that this confusion has
triggered research into cocaine content in urine – also
as a warning to travellers.
Travellers as drug ‘delinquents’?
The alkaloid content of coca leaves has met with wide-
spread interest, up to the minute botanical details of its
distribution throughout the leaf [31]. The mindset firmly
placed on illegality, the possibility of innocents’ positive
drug testing reduced one paper on travel medicine to
only warn against prospective legal trouble without any
further discussion of its use [120]; another mentioned
this aspect briefly in its discussion [25]. However, a few
studies attempted to examine the actual cocaine content
of coca leaf teabags and possible benzoylecgonine (BE)
excretion, a primary urinary metabolite of cocaine
(Table 1). This interest, as the publication dates indicate,
is not only linked to the coca leaf consumption of travel-
lers. From 1983, Delisse, a commercial mate de coca tea-
bag, sold as Inca Health Tea and produced by ENACO
(National Enterprise of Coca, Peru) became a popular
beverage in the US. Though marketed as decocainised,
suspicion lead to several teabag studies that, due to their
diverse designs, cannot be compared and are, therefore,
presented individually in Table 1.
One should pay attention to the measurement units
(e.g. μg, ng). Although the pure cocaine content in a line
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of the illegal drug is hard to judge depending on the
quality (20-30 mg have been suggested [126], up to 2000
mg/day in studies [129] to up to 10 g/day [54]), the
amounts ingested via leaves are not comparable with
those taken up in a cocaine ‘line’. Unless one is in com-
petitive sports or due to drug testing for forensic or
medical purposes, BE in urine is no reason not to use
coca leaves. To discriminate between the use of coca
leaves and manufactured cocaine, hair analysis may be
useful [42, 130].
To put things in perspective, similar studies have been
undertaken with poppy seeds (Papaver somniferum L.), a
Table 1 Studies on cocaine content in coca tea and benzoylecgonine concentration in urine
Authors Year Preparation of infusion Cocaine
content of
infusion
Urinalysis Benzoylecgonine (BE)
concentration in urine
Comments
Siegel
et al.
[121]
1986 N = 36? HIT*: ~ 4.8 mg
Mate de Coca:
~ 5.7 mg
(= 0.13–0.68%
as normally
found in coca)
No evidence of ‘decocainisation’,
No ill effect, no abuse
ElSohly
et al.
[122]
1986 N = 1
1 teabag HIT in 1 cup
2.15 mg 6 samples within
29 h
Total amount
excreted after 29 h:
818.8 μg + 31.1% of
ingested dose.
Consider HIT consumption when
interpreting data
Ferreira-
Engelke
et al.
[123]
1991 40 teabags of HIT
- 20 teabag (1 teabag/cup/10min
- 20 teabags extracted in ethanol/
15 min (method by Turner [124]
X ± SD
0.04% ± 0.017
0.33% ± 0.035
Not decocainised;
If stored for long (e.g. 3 years)
cocaine in brewed tea 0.006–
0.004%, in ethanol extraction
0.06–0.05%
Jackson
et al.
[125]
1991 N = 4 males
1 cup of HIT
1.87 mg Samples over 36
h
Maximum BE
concentration 1.4–
2.8 mg/l
Total BE excretion
in 36 h 1.05–1.45 mg
(= 59–90% of ingested
cocaine)
Consider HIT when interpreting
data
Floren
et al.
[126]
1993 N = 2
1 cup/240ml of tea brought from
Bolivia
Technical
problems
prevented
cocaine
testing.
Estimated 0.8
mg of BE
(3.4 μg/ml)
In one subject 2608
ng/ml after 4 h;
Both subjects negative
after 24 h
Authors concerned about having
had coca tea for 10 days in Bolivia.
‘Experiment’ poorly described.
Emphasise ‘illegality’.
‘Decocainisation cannot be done’
20-30mg per line of cocaine
Jenkins
et al.
[32]
1996 N = 1
Coca teabags from 1) Peru and 2)
Bolivia randomly selected weighed
and tea prepared 1 bag in 180ml
deionized water at 94 °C.
Infusion times: 6, 9, 12, 15 min
Subject drank 1 cup Peruvian tea;
same subject drank 1 cup Bolivian
tea on separate occasion
2 methods of
methanolic
extraction for
both sources
Peruvian tea:
4.14 mg
(range
3.40–4.76 mg)
Bolivian tea:
4.29 mg (range
4.09–4.49 mg)
Samples over 48
h
BE in urine for at least
20 h
Steeping time increased cocaine
content in Peruvian tea (3.94–5.88
mg), approx. 80% of available
cocaine transferred to tea.
Consider tea when interpreting
data.
Turner
et al.
[127]
2005 N = 1
1 teabag of Mate de Coca from
Peru in 250 ml boiling water
Steeped for 25 min.
2.5 mg Samples prior to
consumption and
2, 5, 8, 15, 20, 21,
24, 43, 68 h after
Positive for BE 2–24 h
after consumption
[IB: Nobody would steep tea for
25 min!]
Consider tea when interpreting
data in sports drug testing
Mazor
et al.
[128]
2006 N = 5
1 teabag of Peruvian coca tea in
8 fluid ounces.
Steeped for 15 min
Each volunteer drank 1 more cup
than the previous (A = 1 cup;
B = 2 cups, etc)
Samples prior and
at 2, 12, 24, 36 h
after ingestion
Mean BE
concentration in all
samples: 1777 ng/ml
(95%CI: 1060–2495)
Consider tea when interpreting
data.
*HIT = Health Inca Tea
Bauer Tropical Diseases, Travel Medicine and Vaccines            (2019) 5:20 Page 9 of 14
popular ingredient in a wide variety of food products, to
determine morphine and codeine content in the seeds as
well as metabolites in urine. Results found 2–294 μg/g/
seed of morphine and 0.4–57.1 μg/g/seed of codeine
[131, 132]; > 300 μg/L opiate in urine [131]. Another
study reported highly differing morphine concentrations
depending on variety and type of harvesting (0.5–294
mg/kg/seed) [133]. The inadvertent intoxication of an
infant in 2005 in Germany triggered more comprehen-
sive work [134] pointing to the loss of morphine during
food processing. This led to banning imports of seeds
from Australia containing high concentrations of mor-
phine, and the advice against the consumption of large
volumes of raw poppy seeds. Again, inadvertent positive
drug testing [135], also in oral fluid [136], must be con-
sidered. In contrast to coca leaves, and despite minute
amounts of morphine and codeine in poppy seeds,
people eat them without any concern. Nobody calls for
controlled cultivation of grapes to combat the enormous
health and social cost of alcoholism. Tobacco is the sin-
gle most preventable cause of death in the world [137],
yet, tobacco cultivation appears mainly controlled for fis-
cal, not health reasons. It seems hypocritical to abandon
reason over minute amounts of BE in urine when people
have no trouble ingesting highly toxic substances, heavy
metals, pesticides, herbicides or hormones in their daily
food.
The coca leaf: misunderstood and maligned
The coca leaf has been plagued by ignorance and preju-
dice since the conquest. In the nineteenth century,
Peru’s potential benefit from coca as a keystone marker
of nationality was made impossible by the increasing
cultural divide and racial hierarchy between urban elites
and the coca-chewing Indian majority. When, driven by
intellectuals, the indigenismo movement arrived in the
early twentieth century, coca was demonised as a ‘degen-
erating vice … poisoning … Peru’s raza indigena’ [73].
This relentless view guided many Peruvian researchers
who formed a strong lobby around anti-coca crusader
Dr. Carlos Gutierrez Noriega opposite the more moder-
ate Dr. Carlos Monge [73] and influenced the infamous
ECOSOC report. Peruvian upper and middle classes
have generally viewed indigenous chewing with con-
tempt [58, 73], an attitude that can still be observed
today. Examining literature from within the US context,
bias can often be spotted in the choice of topic, hypoth-
esis, protocol, interpretation, and the continuous use of
the same laden words such as ‘cocaism’ (vs cocainism),
or ‘addicts’ [37, 138, 139], labelling chewing a scourge
and (non-evangelised) chewers ‘infra-social’ [138]. The
term ‘cocaism’, of course, plays into the hands of the un-
informed for whom it is all the same. Biased is also the
thesis that coca chewing leads to miserable living
conditions [eg. 37], a potential association sold as cause-
effect relationship. Indefensible are suggestions that coca
affects a person’s intelligence [37, 47] and the demand
for the eradication of coca leaf use without understand-
ing, consideration and appreciation of the complex trad-
itional and cultural context [41].
Equating coca leaves with the illegal drug cocaine is ab-
surd and has been condemned on many fronts throughout
the decades [64, 88, 89, 140]. According to Toyne, to
transfer critical attitudes about cocaine to coca is inappro-
priate and irresponsible: ‘comparing the physiological ef-
fect of chewing naturally occurring coca leaves to snorting
manufactured cocaine powder is like “comparing fire
hoses with flame throwers” (Karch)’ [46, p.21]. Interest-
ingly, it is precisely this equation (coca = cocaine) why
coca is not used in Ecuador. A combination of colonial re-
ligious and civil prohibitions, a historical lack of a mining
industry, and the wiping out of up to 95% of the indigen-
ous population in some areas meant that knowledge and
use of coca are virtually absent [141]. Depicting coca as a
plant with psychedelic properties used by primitive man
in primitive cultures with pernicious consequences [139]
certainly helped. Today, a 1990 law (Title VI, article 38)
prohibits cultivation, use, gathering, storage or transport
of coca plant or parts for any purpose. The Ecuadorian
public accepts that coca means cocaine and so quietly rati-
fies the status – yet, health shops sell coca teabags [141].
Today, ‘cocaism’ appears to have been replaced there by
alcoholism [142].
The problem with research
It is, of course, easy to criticise the shortcomings of
research on coca and its physiological effect on humans
in earlier times considering the changing worldviews,
personal motivations, differing perceptions, and often
crude research methods with basic equipment. Relating
to the use of coca to prevent AMS in travellers, the lack
of efficacy studies has been noted [6, 19, 20, 143]. How-
ever, to then conclude that coca ‘does not work’ is
premature since we do not know, precisely because there
are no such studies. It needs more than some half-
hearted attempt to include coca in travel medicine
research and then blaming the leaf for not working.
Rigorous medical study is usually understood to be
quantitative laboratory-based research or clinical trials.
Unfortunately, transfer of such results to real life can be
inconsequential. This is the main methodological prob-
lem of studying the effect of coca on travellers. For obvi-
ous reasons, such research would need to be conducted
pre, peri and post trip, including on location at altitude
[144, 145] but the core barrier is the travelling popula-
tions itself.
Each traveller is unique in his or her makeup of a
myriad of physical, mental and medical variables when
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arriving at altitude. Additional confounders unique to
the individual traveller are, for example, length of travel,
time of day, level of stress (e.g. left after work or had a
few days of rest before the trip, heavy luggage, missed
flights), jetlag, physical and mental state, headache, too
little/too much to eat or drink, anxiety regarding the
planned trip, and many more. There is no way travellers
could be matched into experimental and control groups
in any meaningful way. Travellers could not even be
their own control as with each arrival even at the same
location, most if not all variables will have changed. This
is important not only for any biochemical tests but be-
cause what travellers feel (before, after, or without coca)
is subjective and escapes clinical measurement. Ques-
tionnaires and scales can produce crude rankings but
not comparable precise results, no matter how hard one
tries. Trembling knees when the plane door opens at El
Alto or a ‘fuzzy head’ cannot be measured; travellers’ de-
scriptions can be captured in qualitative approaches but
not generalised as is desired in medical research. Fur-
thermore, a most vexing issue with prevention is that
one will never know if it worked because one will never
know if one would have suffered a particular ill without
the preventative measure.
If the prevention has not worked, i.e. the person does
have symptoms regardless, one still does not know if the
measure had been applied appropriately, early enough,
and at the necessary strength. It is virtually impossible to
study ‘what would have been?’ or ‘would it have made a
difference?’. To claim coca has not worked because one
still has headaches does not consider a string of reasons
why this may be so. None of this makes coca a good
topic for ‘rigorous’ research. At this stage, no research
may be better than biased, ideology-driven, policy-
influenced projects that confirm what many like to see
confirmed.
Conclusion
The use of coca leaves by travellers to prevent altitude-
related symptoms in the Andes is widespread, yet meets
with disapproval by the travel medicine community. This
paper aimed not at making a strong case for the use of
coca for this purpose; rather, it presented information
on the plant, its origins and history through the times
and its traditional and cultural value to the peoples in
parts of South America. It then proceeded to the illicit
drug cocaine by explaining its history, its production as
well as the current confusing legal situation, and the
failed ‘War on Drugs’.
The fanatic campaign against the coca leaf based on
religious, racist or self-righteous fervour evident in many
decades of the twentieth century must be understood
within the context of those times, even if it may be hard
to accept today. What should not be accepted today is
that critical questioning and decision-making are still in-
fluenced and dictated by attitudes and laws that are
based on those earlier concepts. Almost two decades
into the twenty-first century, a more enlightened ap-
proach is called for. Ignorance makes people fearful; fear
rarely leads to measured, well-founded decisions, but to
misdirected obsession, zeal, and prejudice. People hear
‘coca’ and automatically think ‘cocaine’. Although scien-
tific evidence supporting the use of coca would help
many to step back and re-calibrate, it is highly unlikely
that there will ever be strong research evidence for or
against coca use in travellers. Travellers will use it re-
gardless. If this paper has assisted in providing more
knowledge about coca and the difference between the
entire coca leaf with its minute amounts of alkaloids
(one of which is cocaine) and the isolated illegally manu-
factured purified drug cocaine hydrochloride – at no
fault of the leaf – it has met its goal. As Paracelsus said:
‘Sola dosis facit venenum’.
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